Special Issue "Antiviral Peptides - From Discovery to Translation"

A special issue of Biologics (ISSN 2673-8449).

Deadline for manuscript submissions: 30 June 2022.

Special Issue Editor

Dr. Kai Hilpert
E-Mail Website
Guest Editor
Institute of Infection and Immunity, St George's University of London, London, UK
Interests: antimicrobial peptides; anti-fungal peptides; anticancer peptides; MDR Pseudomonas aeruginosa; MRSA; MDR E. coli; VRE; peptide libraries; SPOT synthesis
Special Issues and Collections in MDPI journals

Special Issue Information

Dear Colleagues,

The current COVID-19 pandemic illustrates the impact a viral infection can have on our society and on our way of life. There are only a few antivirals available and vaccination is often, where possible, the best way to address viral infections. More research in antiviral drugs is urgently needed also in the sight of possible new crossovers of viruses from the animal kingdom to humans. A rich source to study and develop antiviral molecules are antiviral peptides (AVPs). There are currently 2683 antiviral peptides stored in the antiviral peptide database AVPdb. In addition, several antiviral peptides against SARS-CoV-2 are in clinical trials showing the potential of this class of molecules. 

We are inviting manuscripts on all aspects of antiviral peptides, from discovery to translation. We are looking for original research and reviews. These can be screening, identification, characterization, mode of action, toxicity, efficacy, pharmacodynamics, and application in humans or animals.

Dr. Kai Hilpert
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biologics is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Antiviral peptides
  • Antiviral compounds
  • Antivirals
  • Antimicrobial peptides
  • Drug discovery
  • Drug development
  • Infectious disease
  • Viral infection
  • Pathogenic virus for humans
  • Pathogenic virus for animals

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Article
The Peptide TAT-I24 with Antiviral Activity against DNA Viruses Binds Double-Stranded DNA with High Affinity
Biologics 2021, 1(1), 41-60; https://0-doi-org.brum.beds.ac.uk/10.3390/biologics1010003 - 10 Jun 2021
Viewed by 690
Abstract
The peptide TAT-I24, composed of the 9-mer peptide I24 and the TAT (48-60) peptide, exerts broad-spectrum antiviral activity against several DNA viruses. The current model of the mode of action suggests a reduction of viral entry and also a possible interaction with the [...] Read more.
The peptide TAT-I24, composed of the 9-mer peptide I24 and the TAT (48-60) peptide, exerts broad-spectrum antiviral activity against several DNA viruses. The current model of the mode of action suggests a reduction of viral entry and also a possible interaction with the viral DNA upon virus entry. To further support this model, the present study investigates the DNA binding properties of TAT-I24. DNA binding was analysed by gel retardation of a peptide-complexed DNA, fluorescence reduction of DNA labelled with intercalating dyes and determination of binding kinetics by surface plasmon resonance. Molecular dynamics simulations of DNA-peptide complexes predict high-affinity binding and destabilization of the DNA by TAT-I24. The effect on viral DNA levels of infected cells were studied by real-time PCR and staining of viral DNA by bromodeoxyuridine. TAT-I24 binds double-stranded DNA with high affinity, leading to inhibition of polymerase binding and thereby blocking of de novo nucleic acid synthesis. Analysis of early steps of virus entry using a bromodeoxyuridine-labelled virus as well as quantification of viral genomes in the cells indicate direct binding of the peptide to the viral DNA. Saturation of the peptide with exogenous DNA can fully neutralize the inhibitory effect. The antiviral activity of TAT-I24 is linked to its ability to bind DNA with high affinity. This mechanism could be the basis for the development of novel antiviral agents. Full article
(This article belongs to the Special Issue Antiviral Peptides - From Discovery to Translation)
Show Figures

Figure 1

Back to TopTop